Strauss Law P.L.L.C. Announces Investigation of OvaScience, Inc.
NEW YORK, July 27, 2015 /PRNewswire/ -- Strauss Law P.L.L.C., a litigation firm, has commenced an investigation into OvaScience, Inc. (NASDAQ: OVAS) ("OvaScience") related to potential violations of federal securities laws. If you are an OvaScience shareholder, you are encouraged to contact Strauss Law P.L.L.C. for additional information.
OvaScience (NASDAQ: OVAS) is a public company focused on the discovery, development, and commercialization of new fertility treatments.
On January 8, 2015, OvaScience conducted a Secondary Offering (the "Offering"), selling 2.3 million shares of the Company's common stock at $50 per share.
On March 26 and March 28, 2015, OvaScience announced preliminary results for its AUGMENT fertility treatment. On this news, shares of OvaScience plummeted by 35%. The price of OvaScience securities has declined by over $19.00 per share, or over 40%, from the Offering price.
What You Can Do
If you are an OvaScience shareholder who has purchased shares in connection with the Offering and you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Jesse Strauss at 212-822-1496 or via email at [email protected].
About Strauss Law P.L.L.C.
Strauss Law P.L.L.C. is full service litigation firm with a specialty in, among other related practice areas, shareholder rights and business owner disputes. Strauss Law P.L.L.C.'s founder, Jesse Strauss, has over a decade of experience getting justice for his clients, including trial experience at a top national law firm, litigating complex securities fraud matters at a leading plaintiff side class action litigation firm, and clerking for a U.S. District Court Judge. Jesse takes on the tough cases and gets results. He has been twice selected as a New York "Super Lawyer" by Thompson Reuters for his work.
SOURCE Strauss Law P.L.L.C.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article